0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Treatment of Hyperlipidemic Kidney Graft Recipients with Lovastatin: Effect on LDL-Cholesterol and Lipoprotein (a)

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          An increased incidence of hyperlipidemia places kidney graft recipients at increased risk for cardiovascular disease and may contribute to a decline in graft function. A study was undertaken to evaluate the safety and efficacy of lovastatin in these patients. Twelve kidney graft recipients with stable graft function and a cholesterol (chol) level over 250 mg/dl (6.46 mmol/l) were included. The lipid-lowering treatment consisted of 20 mg lovastatin daily, and all patients received immunosuppression with ciclosporin (CS) and prednisolone. Total chol decreased by 27% (300 ± 56 to 219 ± 28 mg/dl; 7.76 ± 1.45 to 5.66 ± 0.72 mmol/l; p < 0.01), LDL-chol by 35% (220 ± 38 to 143 ± 17 mg/dl; 5.69 ± 0.98 to 3.70 ± 0.44 mmol/l; p < 0.01) and triglycerides by 33% (207 ± 127 to 138 ± 56 mg/dl; 2.36 ± 1.44 to 1.57 ± 0.64 mmol/l; p < 0.05). HDL-chol increased by 10% (57 ± 11 to 63 ± 13 mg/dl; 1.47 ± 0.28 to 1.63 ± 0.34 mmol/l; NS). The ratio of total chol/HDL-chol, a generally accepted risk predictor of atherosclerosis, fell from 5.4 ± 1.3 to 3.3 ± 1.2, p < 0.01. Lipoprotein (a) [lp(a)], an independent risk predictor for atherosclerosis, was also evaluated at baseline and after 6 months of lovastatin treatment and showed a decrease of 39% (32.9 ± 27.6 to 19.9 ± 22.9 mg/dl; 0.85 ± 0.71 to 0.51 ± 0.59 mmol/l; p < 0.05). No adverse side effects were seen at this dosage, and hepatic and renal parameters remained unchanged. In conclusion, our data indicate that 20 mg of lovastatin daily is highly effective in correcting hypercholesterolemia in kidney transplant recipients and is accompanied by a significant drop in lp(a).

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1992
          1992
          12 December 2008
          : 62
          : 4
          : 394-398
          Affiliations
          a3rd Department of Internal Medicine, Division of Nephrology, and bDepartment of Pediatrics, University of Vienna, Austria
          Article
          187087 Nephron 1992;62:394–398
          10.1159/000187087
          1300434
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Categories
          Original Paper

          Cardiovascular Medicine, Nephrology

          Lipoprotein (a), Renal transplantation, Hyperlipidemia, Lovastatin

          Comments

          Comment on this article